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Abstract Efficient immunization against hepatitis B virus
(HBV) and other pathogens with plant-based oral vaccines
requires appropriate plant expressors and the optimization
of vaccine compositions and administration protocols.
Previous immunization studies were mainly based on a
combination of the injection of a small surface antigen of
HBV (S-HBsAg) and the feeding with raw tissue contain-
ing the antigen, supplemented with an adjuvant, and
coming from plants conferring resistance to kanamycin.
The objective of this study was to develop a prototype oral
vaccine formula suitable for human immunization.
Herbicide-resistant lettuce was engineered, stably express-
ing through progeny generation micrograms of S-HBsAg
per g of fresh weight and formed into virus-like particles
(VLPs). Lyophilized tissue containing a relatively low,
100-ng VLP-assembled antigen dose, administered only
orally to mice with a long, 60-day interval between prime
and boost immunizations and without exogenous adjuvant,
elicited mucosal and systemic humoral anti-HBs responses
at the nominally protective level. Lyophilized tissue was
converted into tablets, which preserved S-HBsAg content
for at least one year of room temperature storage. The
results of the study provide indications on immunization
methodology using a durable, efficacious, and convenient
plant-derived prototype oral vaccine against hepatitis B.
Keywords Anti-HBV oral vaccine.Lyophilized plant
tissue.Oral immunization.Plant-based vaccines.
S-HBsAg.Transgenic lettuce
Introduction
In the last 25 years, essential progress has been made in
prophylaxis against hepatitis B (HB) using one of the most
effective and cheapest recombined vaccines (Goldstein and
Fiore 2001). However, one third of the worldwide human
population is still suffering from HB and the number of
hepatitis B virus (HBV) chronic carriers is constantly
growing, mainly in developing countries (Kao and Chen
2002). Insufficient medical infrastructure causes delays or
even failure of mass-scale HB vaccination programs. Thus,
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DOI 10.1007/s13353-010-0001-5reliable and easily implementable prevention methods are
desirable. Oral vaccines, including plant-based formula-
tions, are considered as alternatives or supplements for
standard injection vaccines, since they have the potential
for simplified vaccination procedures against pathogens
penetrating through mucosal membranes or blood (Aziz et
al. 2007; Mestecky et al. 2008).
Research on the development of an oral plant-based
vaccine against the HBV and other pathogens has been
conducted for over 15 years. The small HBV surface
antigen (S-HBsAg) was expressed in tobacco, potato,
lettuce, and other plants, as well as in tissue and cell
suspension cultures. Anti-HBs immune response triggered
by the oral administration of plant material containing S-
HBsAg was shown both in mice (Kapusta et al. 1999;
Richter et al. 2000; Kong et al. 2001; Gao et al. 2003;
Joung et al. 2004) and in humans (Kapusta et al. 1999,
2001; Mason et al. 2003; Thanavala et al. 2005). However,
despite some successes, reproducible and long-lasting oral
immunization by feeding proved to be extremely difficult in
terms of the control of the immunization regime, raw plant
material storage, and its inconvenient administration, which
all might potentially lead to tolerance induction (Kirk et al.
2005). Moreover, previously used plants containing S-
HBsAg exhibited resistance to antibiotics, which limits
their application only to laboratory experiments.
We present here an approach to oral vaccines based on
the low-dose administration of lyophilized tissue, derived
from lettuce expressing S-HBsAg at a high level and
resistant to glufosinate-derived herbicides, as the only
selection marker. Lettuce was chosen as a vaccine producer
since it represents a plant naturally free of harmful
substances, adaptable for cultivation in various conditions,
and simple for processing into formulas of a potential oral
vaccine. Freeze-dried material containing S-HBsAg without
exogenous adjuvants, administered to mice under a con-
trolled regime, induced a mucosal and peripheral humoral
response above the nominal protective titer. Lyophilized
material, both a powdered semi-finished product or con-
verted into tablets, preserved the antigen for at least
one year. The presented results can facilitate the develop-
ment of efficient, durable, and convenient plant-based oral
vaccines for prophylaxis against HB and other diseases.
Materials and methods
Construction of the plant transformation vector
The coding region of S-HBsAg of 681 bp in length was
amplifiedonatemplateoftheplasmidpHB321containingthe
completegenomeofHBVsubtypeayw4 (GenBank accession
no. Z35716), using the following primers introducing BamH
Ia n dPst I restriction sites, respectively: 5’-GGATCCATG-
GATCCATGGAGAACATCACATCAG-3’ (forward) and
5’-CTGCAGTAGAGCTCTTAAATGTATACCCAGAGA-3’
(reverse). The amplified fragment was cloned into the
pMG2A plasmid, a derivative of pUC18 containing the
35 S RNA CaMV promoter (p35S) and nopaline synthase
terminator (NOSt). The expression cassette p35S-SHBsAg-
NOSt was cloned into the EcoR I and Hind III sites of
pGPTV-BAR (Becker et al. 1992), replacing the GUS gene.
The yielded vector pKHBSBAR (Fig. 1), carrying the bar
gene conferring resistance to glufosinate, was introduced into
Agrobacterium tumefaciens EHA105 via electroporation.
Lettuce transformation, regeneration, and cultivation
Agrobacterium tumefaciens was cultured and prepared for
explant inoculation as previously described (Pniewski and
Kapusta 2005), but Agrobacterium was grown until OD550 ≈
1.0. Seeds of lettuce (Lactuca sativa L.) cv. Syrena were
sterilized for 12 min with 20% v/v chloric bleach supple-
mented with 0.01% v/v Tween®20, washed 5–6 times with
distilled water, and germinated on solidified 0.8% w/v agar
(Serva) in the semi-shade at 25°C for 2–3 days. Cotyledons
were then excised, inoculated in the Agrobacterium suspen-
sion for 10–15 min, dried briefly, and transferred onto the
LR1 medium consisting of MS salts and vitamins, 3% w/v
sucrose, 0.2 mgL
−1 of 6-benzylamminopurine, and
0.05 mgL
−1 of naphthaleneacetic acid and co-cultured for
2 days in darkness at 25°C. Explants were transferred once a
week onto fresh LR1 selection medium, i.e., supplemented
with 2.5 mgL
−1 of glufosinate (Sigma) and 300 mgL
−1 of
Timentin. Calli with adventitious buds were transferred onto
the LR2 selection medium consisting of SH salts, B5
vitamins, 3% w/v sucrose, 0.5 mgL
−1 of kinetin, and
0.5 mgL
−1 of zeatin. Developed plantlets were excised and
Fig. 1 Organization of T-DNA of the binary plasmid pKHBSBAR. S-
HBs, coding sequence of small surface antigen of HBV; bar, coding
sequence of phosphinothricin acetyltransferase; p35S, CaMV 35 S
promoter; pNOS, nopaline synthase promoter; NOSt, nopaline
synthase terminator; g7t, g7 terminator; LB and RB, left and right T-
DNA border sequences
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of half the amount of SH macroelements, but the full amount
of SH microelements, B5 vitamins, and 3% w/v sucrose. All
media were adjusted to pH 5.7 and solidified with 0.8% agar
(Serva). In vitro cultures were conducted under 4,000 lx of
light intensity, 16/8-h photoperiod, and at a 25/18°C
temperature regime. Rooted plants were transferred into soil
and grown in a greenhouse under 15–20 klx light intensity,
16/8-h photoperiod, and at a 22/16°C temperature regime.
Harvested seeds were surface-sterilized and germinated as
above on a half-strength MS medium with 2.5 mgL
−1 of
glufosinate. Seedlings of progeny plants were transferred
into soil and cultivated as described above.
PCR and Southern blot analysis
Genomic DNA was extracted from leaves in a small-scale
procedure according to McGarvey and Kaper (1991).
Polymerase chain reactions (PCRs) were performed in a
PTC-200 MJ Research thermal cycler, in a volume of 25 μl
containing approximately 100 ng of plant genomic DNA,
10 pM of each of the above-mentioned primers, 0.2 mM of
each dNTP, 3.5 mM MgCl2, and 1 unit of Taq DNA
polymerase (Invitrogen). The PCR temperature profile was
as follows: initial denaturation at 94°C for 4 min, then 35
cycles of denaturation at 94°C for 1 min, annealing at 68°C
for 45 s, elongation at 72°C for 1 min, and final extension
at 72°C for 5 min. The molecular weight of PCR products
was estimated by agarose gel electrophoresis using the
200 bp DNA Ladder (MBI Fermentas).
DNA for Southern hybridization was extracted according
to Doyle and Doyle (1990), cut with the EcoR I, run on
0.75% agarose gel, and then blotted onto a positively charged
membrane (Roche). The probe specific to the S-HBs
sequence was prepared by PCR using a DIG DNA Labeling
Kit (Roche), hybridized according to the manufacturer’s
protocol, and signals were detected on an X-ray film using
CSPD (Roche) as a chemiluminescent substrate.
TEM
Lettuce leaf tissue was prepared for transmission electron
microscopy (TEM) according to the standard technique
with slight modifications (Kocjan et al. 1996). Ultrathin
sections of approximately 70 nm in thickness were obtained
using an UltraCut S microtome (Leica Microsystems) and
observed under a JEM1200EXII transmission microscope
(Jeol).
Western blot of S-HBsAg
Leaf pieces, approximately 50–60 mg in weight, were
ground in 300 μl of PBS buffer with 0.5% v/v Tween®20,
then Laemmli buffer with DTT was added and samples
were incubated at 65°C for 15 min. Samples were run under
denaturing conditions (12% w/v polyacrylamide gel with
0.1% w/v SDS) and then blotted onto a nitrocellulose
membrane (Roche). The blot was blocked with 3% w/v
BSA in TBS buffer, then incubated with 1:4,000 TBS-
diluted anti-SHBsAg rabbit serum (University of Gdańsk,
Poland) or 1 μg/ml mAb C86132M (Biodesign). The
1:10,000 TBS-diluted anti-rabbit or anti-mouse whole-
molecule polyclonal HRP-conjugated antibody (Sigma)
was used as a secondary antibody. The molecular weight
of protein bands, visualized after a reaction with the DAB
substrate (Sigma), was estimated using a protein marker
(MBI Fermentas).
ELISA assay of S-HBsAg in lettuce leaves, lyophilized
plant tissue, and derived tablets
Samples were ground in a mortar on ice in a gradually
added extraction buffer consisting of PBS pH 7.4, 10 mM
Na2SO3, 2% w/v PVP40000, 0.2% w/v BSA, and 1% v/v
Tween®20. Crude extracts were centrifuged at 10,000 rpm
at 4°C for 10 min. The ratio of extraction buffer volume to
the sample weight was 25:1 for leaf and 200:1 for
lyophilized tissue or tablet.
The quantitative enzyme-linked immunosorbent assay
(ELISA) was performed according to typical guidelines
with details specific for the S-HBsAg assay set as follows.
A Microtiter MaxiSorp (Nunc) microplate was coated
overnight at 4°C with 0.5 μg/ml mAb C86132 (Biodesign)
in carbonate buffer pH 9.6 and then saturated for 2 h at
25°C with 5% w/v PBS-fat-free milk. Typically, extracts
were added to PBS-filled wells and serially diluted 1:100–
1:800 for leaf samples or 1:800–1:6,400 for lyophilized
tissue or tablet samples. Afterwards, wells were incubated
with 1:4,000 anti-SHBsAg polyclonal rabbit antibody
(B65811R, Biodesign), then with 1:20,000 anti-rabbit IgG
γ-specific biotin-conjugated mAb (Sigma), followed by
1:4,000 AP-conjugated ExtrAvidin® (Sigma). The reaction
with pNPP substrate (Sigma) was developed at 25°C for 1
h and absorbance was measured at 405 nm using a Bio-Rad
Microplate Reader, Model 680. The S-HBsAg concentration
(microgram per gram offresh or dry weight, μg/g FWor μg/g
DW, respectively) was calculated as the arithmetic mean with
standard deviation (SD) from three (lettuce leaves) or ten
(lyophilized tissue and tablets) repeated assays, using
Microplate Manager 5.2.1 software (Bio-Rad), according to
the standard curve for unadjuvanted S-HBsAg (University of
Ulm, Germany) in the negative control extract.
As a reference to the above polyclonal ELISA test for
the total content of S-HBsAg, plants were screened using
an Auszyme® Monoclonal Diagnostic Kit (Abbott) for the
virus-like particle (VLP)-assembled antigen. The samples
J Appl Genetics (2011) 52:125–136 127were extracted as above and assayed according to the
provided protocol.
Preparation of lyophilized plant material and tablets
Leaves from lettuce lines of S-HBsAg content ≥10 μg/g
FW were frozen in liquid nitrogen, then partially crumbled
and freeze-dried (BETA 1-16, CHRIST®) in vacuum at
0.2 mbar and −30°C, for 36–72 h. Lyophilized tissue was
powdered in a coffee-mill chilled on ice and stored at room
temperature with silica gel, tightly sealed. For tablet
preparation, the material was mixed with different fillers
and binding agents. Finally, tablets were prepared from
2:1:1 w/w/w mixture of tissue powder with lactose
(Meggle) and 10% w/v polyvinylpyrrolidone (BASF) in
methylene chloride (Merck). The mixture was granulated
into grains of 1 mm in diameter. Granules were mixed with
2% w/v magnesium stearate and then formed in a stamping
press (Korsch) into tablets.
Mouse immunization
Mouseimmunizationstudieswereconductedwithapprovalno.
35/2004 of the Local Bioethical Commission at the Medical
University of Warsaw. Separate groups of 6–8-week-old 10
BALB/c mice were immunized with powdered lyophilized
plant tissue containing S-HBsAg or the purified and alum-
adsorbed yeast-derived antigen from a commercial vaccine
Engerix B® (GlaxoSmithKline) at 30- or 60-day intervals. A
single dose of VLP-assembled S-HBsAg was 100 ng, sus-
pended in 100 μl of PBS, and administered by gavage
intubation. Directly before immunization, VLP-S-HBsAg was
assayed by the Auszyme® kit to deliver an appropriate amount
of the lyophilized plant material (ca. 9 mg/dose). Control mice
were given lyophilized non-transgenic tissue or PBS every
60 days.
ELISA assay of anti-HBs antibodies and statistical analysis
of immune response
Blood and feces were collected 5 days before (pre-immune)
and 10 days after each immunization. Sera were collected
from blood centrifuged at 3,000 rpm at 4°C for 10 min.
Antibodies were extracted from feces by suspending
samples in five volumes (w/v) of PBS and incubation on
ice for 15 min, twice repeated grinding and incubation on
ice for 15 min, and shaking and centrifugation at
14,000 rpm at 4°C for 10 min. Anti-HBs antibodies
(mIU/ml) were assayed twice using a Hepanostika® kit
with quantitative standards (Organon Teknika, Boxtel) and
analyzed statistically (the variance for one-way classifica-
tion with repeated measurements, the Tukey and Duncan
tests, p<0.05) using Statistica 6® software (StatSoft).
Results
S-HBsAg expression in glufosinate-resistant transgenic
lettuce plants
The efficiency of lettuce transformation amounted to 13%,
i.e., 25 verified (out of 28) PCR-positive for S-HBs sequence,
individual glufosinate-resistant transgenic lines were regen-
erated from 190 explants. The S-HBs sequence was detected
by PCR in ≥75% of the 25–35 progeny (T1) plants of each
analyzed line (Fig. 2a), and in most lines, Southern blot
analysis confirmed 1–2 integration sites of T-DNA (Fig. 2b).
The primary (T0) transformants significantly differed
regarding the total S-HBsAg expression (20 ng to 60 μg/g
FW), hence, they were distinguished into three expression
groups, i.e., of ‘low’ antigen level ≤5 μg/g FW, ‘medium’
5–10 μg/g FW, and ‘high’ ≥10 μg/g FW (Fig. 3). The S-
HBsAg content was maintained or increased in plants of the
Fig. 2 a, b Inheritance of the S-HBs transgene in lettuce plants of T1
generation. a PCR analysis using primers designed to the S-HBsAg
coding sequence to amplify a 693-bp product. Lanes: M DNA size
marker (200 bp DNA Ladder, MBI Fermentas); 6A/1–26G/10
analyzed plants; N non-transgenic plant (negative control); P
pKHBSBAR plasmid (positive control). b Southern blot analysis of
integrated T-DNA in genomic DNA using a probe complementary to
the S-HBs sequence. Lanes: 4D/5–26G/5 analyzed plants; N non-
transgenic plant (negative control); P pKHBSBAR plasmid (positive
control)
128 J Appl Genetics (2011) 52:125–136T1 generation for most lines of the ‘low’ or ‘medium’
groups. Significant fluctuations and decrease of antigen
expression or some phenotype alterations, e.g., retarded
growth or a low number of seed sets, were observed only
for a few lines, mostly from the ‘high’ group. Finally, 12
lines of stable S-HBsAg content ≥5 μg/g FW were selected
for further research, including ‘high’ lines designed for
lyophilization. The content of S-HBsAg formed in tertiary
structures, i.e., displaying immunodominant epitope ‘a’
when properly folded and assembled into VLPs, was
estimated using an monoclonal Auszyme® kit (Abbott),
being approximately 60–85% of the total values calculated
by the polyclonal ELISA (Fig. 3). The expression of S-
HBsAg assembled into dimers, both non-glycosylated
(48 kDa, p48) and putative glycosylated (54 kDa, gp54),
was also confirmed by Western blot analysis (Fig. 4). VLPs
formed by plant-expressed S-HBsAg were directly ob-
served in leaf cells using TEM (Fig. 5a, c), while they were
not detected in non-transgenic lettuce (Fig. 5b). Observed
plant VLPs were 17–22 nm in diameter, characteristic of
native or yeast-derived purified VLPs (Fig. 5d).
Mouse immunization with lyophilized plant tissue
containing S-HBsAg
Several trends in local and systemic humoral immune
responses were observed after the oral delivery of 100 ng/
dose of VLP-assembled S-HBsAg, both plant-derived in
powdered lyophilized tissue (ca. 9 mg/dose, coming from
plants of ≥10 μgS-HBsAg/g FW) or the purified and alum-
adsorbed antigen (Fig. 6). Anti-HBs antibodies, both
secretory IgA (S-IgA) in feces (Fig. 6a) and total serum
antibodies (Fig. 6b), were induced at similar levels in all
individual mice of particular groups, as demonstrated by
low SDs. Immune response was clear and statistically
significant for each immunization protocol, but more efficient
for the longer schedule. The final levels of anti-HBs
antibodies were similar for reactions induced by the
plant-derived or purified antigen administered every
30 days, but for the 60-day schedule, plant-derived
antigen elicited a higher immune response, especially in
the mucosa. The systemic response was lower than that
in the intestinal mucosa, approximately 3–4t i m e sl o w e r
after priming and almost 2 times lower after boosting.
However, serum anti-HBs antibodies reached the level
above the cut-off value of 10 mIU/ml, accepted as the
minimal protective titer.
Preparation of a plant-derived prototype for orally
administered vaccine
Lettuce leaves, harvested from T1 plants of S-HBsAg
content ≥10 μg/g FW, were freeze-dried and ground into
powder and stored at room temperature with a desiccating
silica gel. This semi-product was mixed with different
fillers and binding agents, e.g., mono- and oligosaccharides,
starch, cellulose derivatives, gelatine, Arabic gum, inorganic
compounds, etc. Finally, the 2:1:1 w/w/w mixture of the
powdered plant tissue with lactose as the filler and a
10% w/v polyvinylpyrrolidone/methylene chloride as the
binding agent met the required powder density and
consistency suitable for the preparation of standard
tablets, i.e., 10×3-mm in size and 500 mg in weight,
with appropriate durability, friability, dissolution time,
and possibility of room temperature storage (Fig. 7a).
The level of total S-HBsAg in the lyophilized material
reached 5 mg/g FW. However, the mean content of VLP-
structuralized antigen was 11 μg/g of lyophilized tissue
and 5 μg/g or 2.3 μg/unit of tablets, i.e., approximately
half that of the original lyophilized material due to the
added ingredients. The antigen level remained stable, i.e.,
without significant fluctuations, after one year of storage
in dry air at room temperature, both in lyophilized tissue
and in tablets (Fig. 7b).
Fig. 3 Expression of total and VLP-assembled S-HBsAg in lettuce
plants of T0 and T1 generation. Plants of T0 generation were divided
into three expression groups, depending on the total S-HBsAg level
calculated in μg/g of fresh weight (FW): low <5 μg/g FW, medium 5–
10 μg/g FW, high >10 μg/g FW. The data show values calculated as
the arithmetic mean and standard deviation (SD) from three assays for
parental or 25–35 progeny plants, determined by polyclonal ELISA
for total antigen or by the monoclonal Auszyme® diagnostic kit
(Abbott) for VLP-assembled antigen
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Glufosinate-resistant lettuce expressing S-HBsAg
as an initial material for plant-derived prototype oral
vaccine against HBV
The presented transformation and regeneration procedure
made it possible to obtain independent glufosinate-resistant
lettuce line plants with a 13% efficiency. The value is lower
than 70% or 31% (Enomoto et al. 1990; Curtis et al. 1994)
but comparable to 6% or 10% reported previously
(Michelmore et al. 1987; Torres et al. 1993). The selection
system based on the marker gene bar (Fig. 1), conferring
resistance to strongly acting glufosinate, probably reduced
the transformation rate, but, on the other hand, it guarantees
high probability (90%, see Results section) of regeneration
of authentic transformants in comparison to kanamycin
(Mohapatra et al. 1999). The obtained 25 plant lines were
analyzed to select 12 lines characterized by a normal
phenotype, stable inheritance of the S-HBs transgene
Fig. 4 Western blot analysis of S-HBsAg in lettuce. Lanes: M protein
molecular weight marker (MBI Fermentas); 4D/4–26G/1 analyzed
plants; N non-transgenic plant (negative control); P S-HBsAg
(positive control, University of Ulm, Germany). The arrows indicate
non-glycosylated (p48) and putative glycosylated (gp54) dimers (48
and 54 kDa) of covalently linked S-HBsAg units
Fig. 5 a–d Transmission
microscope analysis
(JEM1200EXII, Jeol) of
virus-like particles (VLPs)
assembled by plant-expressed
S-HBsAg. a VLPs in the
endoplasmic reticulum (ER)
and the nuclear envelope (Ne)
of transgenic lettuce cell,
magnification 3.6 × 10
4,
bar=100 nm. b Nuclear
envelope (Ne) of non-transgenic
cell, magnification 3.6 × 10
4,
bar = 100 nm. c VLPs inside ER
vesicles, enlarged section
of panel a), magnification
7.2 × 10
4, bar=50 nm. d
Yeast-derived purified VLPs
in Engerix B®, magnification
7.2 × 10
4, bar = 50 nm
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satisfactory level of 5–20 (and more) μg of S-HBsAg/g
FW, both in T0 and T1 generations (Fig. 3). The observed
average S-HBsAg expression level was similar or higher in
comparison to the 0.05–16 μg/g FW reported in previous
papers (e.g., Kapusta et al. 1999; Richter et al. 2000; Kong
et al. 2001; Gao et al. 2003; Sojikul et al. 2003; Joung et al.
2004; Shulga et al. 2004; Huang et al. 2005), reaching
60 μg/g FW in some plants. The expression of native
antigen forming tertiary structures was confirmed, since the
Auszyme® or other diagnostic kit assays require specific
binding of a monoclonal antibody to a displayed immuno-
dominant epitope ‘a’ of S-HBsAg assembled into VLPs
(Jolivet-Reynaud et al. 2001; Sojikul et al. 2003). Protein
bands of 48 and 54 kDa, revealed by Western blot analysis,
correspond to unmodified and glycosylated S-HBsAg
dimers (Fig. 4). Presumably, the dimers are extremely
durable and could be observed under standard denaturing
conditions, since highly hydrophobic S-HBsAg is known to
dimerize immediately post-translation, and units are addi-
tionally cross-linked by multiple disulfide bridges (Bruss
2007). The dimers indicate the first step of VLP self-
assembly (Bruss 2007; Patient et al. 2007), observed also in
plant cells (Joung et al. 2004; Shulga et al. 2004; Huang et
al. 2005). Consequently, VLPs in lettuce were structurally
identical to the yeast-derived particles utilized for vaccina-
tion (Fig. 5), similarly to previous observations in plant
(Kong et al. 2001) and mammalian cells (Patient et al.
2007).
In addition to the relatively high S-HBsAg expression
level, the presented transgenic lettuce represents some
benefits as an oral vaccine producer. The glufosinate-
resistant lettuce conforms to GMO safety regulations and
health requirements, since it is free of an antibiotics-
resistance marker gene. The cultivation of lettuce does not
require special conditions and can be adapted to various
local needs. Disadvantageously, the amount of harvested
material is substantially lower than from typically exploited
Fig. 6 Anti-HBs secretory IgAs
(S-IgAs) in feces extract (a) and
total serum antibody response
(b) to oral immunization with
100 ng/dose of VLP-assembled
S-HBsAg. Mice were
immunized with lyophilized
plant tissue (ca. 9 mg dry
weight/dose) or purified antigen,
and delivered at 30- or 60-day
timings. Non-transgenic
lyophilized tissue or PBS were
delivered to control mice at a
60-day timing. Anti-HBs
antibody level (mIU/ml)
responses are expressed as
arithmetic means with standard
deviations (SD) from results for
10 BALB/c mice at pre-immune
(5 days before prime) and
10 days after each immuniza-
tion, determined twice by a
Hepanostika® kit (Organon
Teknika, Boxtel). Statistically
homogenous or significantly
distinct responses for S-IgAs or
total serum antibodies are
marked by identical or different
letter indexes, respectively
(Tukey and Duncan tests,
p<0.05, Statistica 6®)
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harmful alkaloids, etc., and the antigen concentration can be
increased by lyophilization. Lettuce leaves are easy to be
freeze-dried in comparison to tomatoes, bananas, tubers, or
carrot. Moreover, though lyophilization is necessary, S-
HBsAg expression level in leaves is many times higher
than in naturally dry seeds (Sunil Kumar et al. 2006).
Oral immunization with lyophilized plant tissue containing
S-HBsAg
Potential plant-based oral vaccines require suitable antigen
formulations and immunization protocols to ensure antigen
stability through the alimentary tract and a balance between
immune response and oral tolerance (Holmgren and
Czerkinsky 2005; Mestecky et al. 2007).
The presented results show that a relatively low dosage,
i.e., 100 ng of S-HBsAg VLPs, and an extended interval,
up to 60 days between oral prime and boost, induced
mucosal and systemic efficient immunization with a small
amount of lyophilized tissue, ca. 9 mg (Fig. 6). The level of
S-IgAs was somewhat higher than serum antibodies,
similarly to some previous observations (Shchelkunov et
al. 2006; Jiang et al. 2007). Response of the gut-associated
lymphoid tissue (GALT) to the antigen administered solely
orally could surpass periphery response, since GALT
interacts with such antigens as the first line of the whole
immune system and also mucosal membranes limit deeper
antigen penetration (Czerkinsky et al. 1993), but on the
other hand, mucosal immunity can broaden the protection
range against penetrating pathogens (Isaka et al. 2001;
Brandtzaeg 2003). Nevertheless, the antigen delivered on
the described schedule elicited a statistically significant
mucosal and systemic response in comparison to the pre-
immune and the control, finally reaching a titer ≥10
mIU/ml of anti-HBs total serum antibodies (Fig. 6b),
which is considered as the minimal protective response
(International Group 1988;B r o c k ee ta l .2005). A low S-
HBsAg dosage induced significant and similar immune
responses in individual mice, as demonstrated by low SDs
(Fig. 6), probably due to the fact that the GALT is a tuned
immune milieu, where even small amounts of antigens
organized into VLPs or other tertiary structures are
recognized and processed (Mestecky et al. 2007). Conse-
The GALT determines adaptive immunity versus unre-
sponsiveness depending on antigen structure dosage and
duration of its exposure (Mowat 2003;P a m e r2007).
Accordingly, low antigen dosage applied in the study was
probably conducive to local and systemic immune
response, while oral tolerance can be induced by high
dosage and/or repeated frequent antigen delivery (Peng et
al. 1989; Friedman and Weiner 1994).
Other reports on oral immunization with S-HBsAg or
other antigens corroborate the positive effect of a low
Fig. 7 a, b Plant-based
prototype of anti-HBV vaccine
specimens. a Preparation of
plant-derived materials. Panels:
left lettuce plants expressing
≥10 μg S-HBsAg/g FW; middle
powdered lyophilized plant
tissue as a semi-finished product
for the preparation of various
formulas of an oral vaccine;
right tablets of 10×3 mm in size
and 500 mg in weight, contain-
ing a specific dose of S-HBsAg.
b The level of total and
VLP-assembled S-HBsAg in
powdered lyophilized tissue and
1 g and 1 unit of tablets, freshly
prepared and stored for one
year. S-HBsAg content was
calculated in μg/g of dry weight
(DW) as an arithmetic mean and
standard deviation (SD) from
ten polyclonal ELISA or
monoclonal Auszyme® assays
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quently, the local immune response develops and immu-
nity can be transmitted from the mucosa to the periphery.antigen dosage and extended administration on immune
response. A 5-ng dose of alum-adsorbed S-HBsAg admin-
istered orally to mice over 8 weeks induced a significantly
higher response than a 500-ng dose delivered over 2 weeks
(Kapusta et al. 2010), or the response was higher and
reached the ≥10 mIU/ml protective level in human
volunteers fed with lettuce on days 1 and 60 (Kapusta et
al. 1999) than in those fed on days 1, 7, and 30 (Kapusta et
al. 2001) with 1–2 μg of S-HBsAg per person. According-
ly, low nanogram doses of S-HBsAg elicited immune
response both in the mucosa and the periphery, while higher
doses stimulated tolerance (Kostrzak et al. 2009); primary
humoral response was triggered at an oral delivery of 30 ng
of fusion antigen TBI-HBsAg to mice and the successive
boost by DNA immunization only slightly increased the
level of anti-HBs antibodies (Shchelkunov et al. 2006). The
efficacy of oral immunization conducted at a low, even
nanogram, dosage and at extended timing was also
confirmed for plant-expressed CT-B (Arakawa et al. 1998)
or LT-B (Lamphear et al. 2002; Beyer et al. 2007). Also for
dietary allergen ovalbumin, low dosage elicited immune
response, while suppression was induced by high-dose
early boosting (Franco et al. 1998).
Plant-associated S-HBsAg, delivered on the reported
schedule and without exogenous adjuvants, elicited an
immune response at the nominally protective level,
although the antibody titer was several times lower than
that usually triggered in cases of S-HBsAg parenteral
administration (Brocke et al. 2005) or previous oral
immunization trials using microgram doses of the antigen.
However, in those experiments, it was necessary to
combine the oral delivery of (in most cases) CT-B-
adjuvanted S-HBsAg with parenteral (prime or boost)
vaccination (Richter et al. 2000; Kong et al. 2001; Gao et
al. 2003; Mason et al. 2003; Joung et al. 2004; Huang et al.
2005; Thanavala et al. 2005). A similar trend of high
immune responses following parenteral–oral abundant
antigen delivery was also observed for other antigens,
e.g., Norwalk virus, rabies glycoprotein, or plague. On the
other hand, parenterally–orally administered micrograms of
the alum-adsorbed antigen, but unadjuvanted with CT-B
(Kong et al. 2001), or the purified and encapsulated antigen
adjuvanted with bile salt or CpG oligos (Borges et al. 2007;
Shukla et al. 2008), induced immune response comparable
to the present results. Immune reaction at the level 10–30
mIU/ml requires to be enhanced though. However, toxin-
derived adjuvants are not approved for use in humans,
hence, any GALT immunostimulator must be meticulously
explored to eliminate possible hazardous side-effects
(Brandtzaeg 2003).
On the other hand, it might be supposed that some
phytochemicals could synergistically affect the immunoge-
nicity of plant-expressed antigens as in the case of
presented results or plant-expressed CT-B (Jiang et al.
2007). Medicinal plants are known for their natural
immunostimulating or anti-microbial activity due to such
secondary metabolites as lectins, saponins, and others.
Lettuce does not contain significant amounts of these
substances though, except terpenoids in latex sap, charac-
teristic for the Asteraceae family. Moreover, some com-
monly occurring plant components have adjuvant
properties, e.g., unmethylated CpGs motifs of DNA (Wang
et al. 2002) or carotenoids, etc. Presumably, plant tissue
together with the above-mentioned compounds protected
and increased the immunogenicity of S-HBsAg in lettuce,
since the reaction elicited by plant-associated antigen was
somewhat higher than that induced by the purified and
alum-adsorbed antigen (Fig. 6). Hence, it might be carefully
assumed that raw edible plants can be used at the same time
as an oral vaccine producer and, at least partially, as a
source of endogenous adjuvants too.
A plant-derived durable prototype for an orally
administered vaccine against hepatitis B
Although oral immunization based on the consumption of
raw transgenic plants containing S-HBsAg was demon-
strated to induce an immune response in mice (Kapusta et
al. 1999; Richter et al. 2000; Kong et al. 2001; Gao et al.
2003; Joung et al. 2004) and humans (Kapusta et al. 1999,
2001; Mason et al. 2003; Thanavala et al. 2005), immuni-
zation by feeding encounters logistical and medical contra-
indications (Kirk et al. 2005). Antigen instability in stored
plant tissue and splitting of an initial dose of ‘edible
vaccine’, both fresh and dry, into lower undefined sub-
doses, repeatedly exposed to GALT, and adsorbed as a
dietary component (Swarbrick et al. 1979), subsequently is
conducive to tolerance induction. Moreover, potential plant-
based oral vaccines considered for mass immunization
against HB and other diseases (Aziz et al. 2007; Mestecky
et al. 2008) should be simple to administer. Expectations
for plant-derived oral vaccines can be met by the
application of freeze-dried plant materials, which was
initiated in recent years in immunization experiments with
monomeric and oligomeric antigens, such as CT-B (Huang
et al. 2005), LT-B (Rosales-Mendoza et al. 2009), measles
hemagglutinin (Webster et al. 2006), and others.
Here, a novel prototype plant-based anti-HBV vaccine in
tablet form prepared from freeze-dried lettuce highly
(≥10 μg/g FW) expressing VLP-assembled S-HBsAg is
proposed (Fig. 7a). The administration of durable powdered
freeze-dried plant tissue made it possible to concentrate and
standardize antigen content throughout vaccine doses and
would facilitate delivery of the antigen in a size-reduced
specimen under a controlled regime (Figs. 6 and 7).
However, during lyophilization, an at least 90% decrease
J Appl Genetics (2011) 52:125–136 133of S-HBsAg VLPs content was recorded when compared to
fresh tissue (Fig. 3) and that observed in freeze-dried tissue
(Fig. 7b), considering that the dry weight is 5–10% FW.
Advantageously, the low dose of VLPs applied in a ‘single
shot’, avoiding extended exposure in sub-portions,
appeared to be sufficient to induce local and systemic
humoral response at an adequate protection level (Fig. 6).
However, potential industrial production of the oral vaccine
would require the optimization of freeze-drying parameters
to effectively retain the VLPs.
The tablet form of a potential vaccine specimen seems to
be feasible to produce, durable in storage even at room
temperature, and easy to use, which is especially important
in regions with an underdeveloped medical infrastructure.
A compact tablet form made it possible to concentrate the
dose of antigen assembled into immunogenic VLPs
(2.3 μg/unit) in a relatively small weight and volume (see
Results section), while the same antigen dose would have to
be contained in a 4–5 times bigger capsule or other formula
containing loose powder. Due to the powdery structure,
high hygroscopicity, and low density of milled lyophilized
tissue, the tablet filler, i.e., lactose, and the binding agent,
i.e., polyvinylpyrrolidone, had to be established experimen-
tally from among standard components to facilitate the
compression of tablets of proper parameters (see Results
section). Moreover, tablets, as well as lyophilized tissue, are
characterized by the stability (95–98%) of S-HBsAg
content for at least one year of room temperature storage
(Fig. 7b). Tablets indicate a direction for the development
of a compacted prototype oral vaccine, convenient for use
and distribution, and may facilitate human immunization
trials. It could be assumed that data acquired on immuni-
zation efficacy will contribute to further tablet optimization
to enhance immune response, e.g., with the addition of
adjuvants, immunomodulators, etc.
Conclusions
Research on a plant-derived vaccine against hepatitis B
virus (HBV) requires further detailed studies on mucosal
and systemic immune response and possible tolerance
induction. Parameters of oral vaccination, such as dosage,
timing, adjuvants, antigen formulation, immunization
routes, etc., will have to be accurately adjusted. The
presented results and other reports allow to carefully
presume that immunity, probably balanced with tolerance,
may be induced by an appropriate immunization protocol,
based on a calibrated, extended delivery timing of generally
low doses of lyophilized tissue containing small surface
antigen of HBV (S-HBsAg). Lettuce or other plants
efficiently expressing native S-HBsAg, resistant to herbi-
cides and innately free of harmful substances, could be an
initial material for the preparation of durable and reliable
oral vaccine as tablets or other formulas. The reported
results constitute a basis for the elaboration of an alternative
or supplementary oral vaccine, easily implementable for
HB immunization programs.
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